1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 United States Idiopathic Pulmonary Fibrosis Treatment Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Drug Class
6.1 MAPK Inhibitors
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Tyrosine Inhibitors
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Autotaxin Inhibitors
6.3.1 Market Trends
6.3.2 Market Forecast
7 Market Breakup by End User
7.1 Hospitals
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Long-term Care Facilities
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Others
7.3.1 Market Trends
7.3.2 Market Forecast
8 Market Breakup by Region
8.1 Northeast
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Midwest
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 South
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 West
8.4.1 Market Trends
8.4.2 Market Forecast
9 SWOT Analysis
9.1 Overview
9.2 Strengths
9.3 Weaknesses
9.4 Opportunities
9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes
12 Price Analysis
13 Policy and Regulatory Landscape
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
List of Figures
Figure 1: United States: Idiopathic Pulmonary Fibrosis Treatment Market: Major Drivers and Challenges
Figure 2: United States: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2018-2023
Figure 3: United States: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 4: United States: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Drug Class (in %), 2023
Figure 5: United States: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by End User (in %), 2023
Figure 6: United States: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Region (in %), 2023
Figure 7: United States: Idiopathic Pulmonary Fibrosis Treatment (MAPK Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
Figure 8: United States: Idiopathic Pulmonary Fibrosis Treatment (MAPK Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 9: United States: Idiopathic Pulmonary Fibrosis Treatment (Tyrosine Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
Figure 10: United States: Idiopathic Pulmonary Fibrosis Treatment (Tyrosine Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 11: United States: Idiopathic Pulmonary Fibrosis Treatment (Autotaxin Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
Figure 12: United States: Idiopathic Pulmonary Fibrosis Treatment (Autotaxin Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 13: United States: Idiopathic Pulmonary Fibrosis Treatment (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
Figure 14: United States: Idiopathic Pulmonary Fibrosis Treatment Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 15: United States: Idiopathic Pulmonary Fibrosis Treatment (Long-term Care Facilities) Market: Sales Value (in Million US$), 2018 & 2023
Figure 16: United States: Idiopathic Pulmonary Fibrosis Treatment (Long-term Care Facilities) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 17: United States: Idiopathic Pulmonary Fibrosis Treatment (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
Figure 18: United States: Idiopathic Pulmonary Fibrosis Treatment (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 19: Northeast: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 20: Northeast: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 21: Midwest: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 22: Midwest: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 23: South: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 24: South: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 25: West: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
Figure 26: West: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 27: United States: Idiopathic Pulmonary Fibrosis Treatment Industry: SWOT Analysis
Figure 28: United States: Idiopathic Pulmonary Fibrosis Treatment Industry: Value Chain Analysis
Figure 29: United States: Idiopathic Pulmonary Fibrosis Treatment Industry: Porter’s Five Forces Analysis
List of Tables
Table 1: United States: Idiopathic Pulmonary Fibrosis Treatment Market: Key Industry Highlights, 2023 and 2032
Table 2: United States: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
Table 3: United States: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by End User (in Million US$), 2024-2032
Table 4: United States: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 5: United States: Idiopathic Pulmonary Fibrosis Treatment Market: Competitive Structure
Table 6: United States: Idiopathic Pulmonary Fibrosis Treatment Market: Key Players